For Jacob Van Naarden, Executive Vice President and President of Lilly Oncology, the mission is clear: bring better cancer ...

Eli Lilly will not seek a broad FDA approval for a combination of the company’s oral SERD med Inluriyo and CDK4/6 inhibitor ...

The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many ...

Eli Lilly’s next-generation obesity treatment may prove highly effective for patients who have high BMI or suffer from ...

LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer valuation.

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is ...

Eli Lilly 's (NYSE: LLY) share price has soared over the past five years (up 530%). In fact, it's hard to find a single ...

In this video, Halle C. F. Moore, MD, discusses the EMBER-3 study update evaluating imlunestrant for women with hormone receptor-positive, HER2-negative breast cancer, presented at San Antonio Breast ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

The Greater Philadelphia life sciences ecosystem has over 1,200 life sciences establishments, including 450 biotech research ...

Eli Lilly and Co shared updated results of Inluriyo (imlunestrant) from a Phase 3 study in previously treated breast cancer patients.

I am bullish on healthcare stocks, especially pharmaceuticals, due to conservative valuations. Check out the healthcare ...